Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The move up comes as the S&P 500 (SNPINDEX: ^GSPC) ...
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.
Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...
Breathe in the fresh air and soak up the beautiful views on this short, sweet, and romantic hike in Vermont. It's the perfect ...
However, for couples who prefer a getaway all to themselves, the most romantic Airbnbs in New York are waiting. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback